The cytosolic branched-chain amino acid aminotransferase inhibitor BCATc Inhibitor 2, which protects oleic acid-induced lipid accumulation and apoptosis, is a promising candidate for the treatment of Non-alcoholic fatty liver disease (Lu et al., 2022). The gene discussed is BCAT1; the disease is metabolic dysfunction-associated steatotic liver disease.